Elevance Health (ELV) EBITDA Margin (2009 - 2026)

Elevance Health (ELV) has reported EBITDA Margin for 18 consecutive years, with 1.39% the latest figure, recorded in Q2 2026.

• On a quarterly basis, EBITDA Margin rose 42.0% year-over-year to 1.39% in Q2 2026; TTM through Jun 2026 was 1.29%, a 15.0% increase from a year earlier, with the FY2025 full-year figure at 1.1%, down 6.0% from the prior year.
• EBITDA Margin was 1.39% for Q2 2026 at Elevance Health, down from 1.52% in the prior quarter.
• Over five years, EBITDA Margin peaked at 1.52% in Q1 2026 and troughed at 0.92% in Q1 2023.
• A 5-year average of 1.11% and a median of 1.12% in 2023 frame the typical range for EBITDA Margin.
• Across the five-year window, EBITDA Margin dropped 20 bps in 2022 and soared 42 bps in 2026, its largest moves.
• Over 5 years, EBITDA Margin stood at 0.93% in 2022, then surged by 33 bps to 1.24% in 2023, then slipped by 7 bps to 1.16% in 2024, then fell by 15 bps to 0.99% in 2025, then surged by 41 bps to 1.39% in 2026.
• The last three EBITDA Margin figures came in at 1.39% (Q2 2026), 1.52% (Q1 2026), and 0.99% (Q4 2025), per Business Quant data.